← 홈

전체 프로그램

ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-7 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 545개
AntibodystaleGlaxoSmithKlinePhase 2

tositumomab (tositumomab)

Lymphoma, B-Cell · Lymphoma

#Lymphoma#Antibody#Phase2#항체#면역항체+3
효능 ORR 1%임상시험 1상태 ACTIVE
CGTBiologicstaleInstitute of Hematology & Blood…Phase 1

uCD7 CART (uCD7 CART)

Acute Myeloid Leukemia (AML); T Lymphoblastic Leukemia/Lymphoma · Acute Myeloid Leukemia (AML)

#AcuteMyeloidLeukemiaAML#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
AntibodystaleBeth ChristianPhase 2

veltuzumab (veltuzumab)

Lymphoma · Lymphoma

#Lymphoma#Antibody#Phase2#항체#면역항체+2
효능 ORR 24%임상시험 1상태 ACTIVE
AntibodystaleBeth ChristianPhase 2

veltuzumab and milatuzumab (veltuzumab and milatuzumab)

Lymphoma · Lymphoma

#Lymphoma#Antibody#Phase2#항체#면역항체+2
효능 ORR 24%임상시험 1상태 ACTIVE
AntibodystaleAIDS Malignancy ConsortiumPhase 2

yttrium Y 90 ibritumomab tiuxetan (yttrium Y 90 ibritumomab tiuxetan)

AIDS-related Lymphoma; Adult Non-Hodgkin's Lymphoma · AIDS-related Lymphoma

#AIDS-relatedLymphoma#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 DISCONTINUED

28 / 28 페이지

← 이전다음 →